Last $3.76 USD
Change Today -0.02 / -0.53%
Volume 589.3K
CUR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

neuralstem inc (CUR) Snapshot

Open
$3.80
Previous Close
$3.78
Day High
$3.82
Day Low
$3.68
52 Week High
06/4/14 - $4.81
52 Week Low
10/20/14 - $2.12
Market Cap
328.5M
Average Volume 10 Days
1.1M
EPS TTM
$-0.24
Shares Outstanding
87.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEURALSTEM INC (CUR)

neuralstem inc (CUR) Related Bloomberg News

View More Bloomberg News

neuralstem inc (CUR) Details

Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. The company’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical program products include NSI–566, which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, and Phase I clinical trials for chronic spinal cord injury. The company’s clinical development products also comprise NSI–566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; and NSI–189 that is in Phase Ib for the treatment of major depressive disorders. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.

15 Employees
Last Reported Date: 11/7/14
Founded in 1996

neuralstem inc (CUR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $651.2K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $675.4K
Compensation as of Fiscal Year 2013.

neuralstem inc (CUR) Key Developments

Neuralstem, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 09:00 AM

Neuralstem, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 09:00 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: I. Richard Garr, Co-Founder, Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, General Counsel and Director.

Neuralstem, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 03:30 PM

Neuralstem, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 03:30 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: I. Richard Garr, Co-Founder, Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, General Counsel and Director.

Neuralstem, Inc. Announces Blood-Based Biomarkers for Major Depressive Disorder (Mdd) Identified a Rapid Response to NSI-189 in the Phase Ib MDD Trial

Neuralstem, Inc. announced that blood-based biomarkers for major depressive disorder (MDD) identified a rapid response to NSI-189 in the Phase Ib MDD trial. These results are consistent with clinical data results, reported at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in June, that showed a significant number of patients on active treatment demonstrated clinical improvement by a reduction in total Montgomery- sberg Depression Rating Scale (MADRS) scores 15.9 points, which continued 8 weeks after dosing stopped. This sustained drop was to a point at, or near, what is usually associated with remission on SSRI compounds. MADRS is a commonly-used clinical assessment scale to determine depression severity. NSI-189 is Neuralstem's first-in-class, lead neurogenic small molecule compound, shown to promote neurogenesis in vitro. In animal studies, NSI-189 resulted in a significant increase in hippocampal volume. Quantative EEG Phase Ib analysis, also reported in June, showed that active therapy patients had significantly increased brain wave patterns in the hippocampal region of the brain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUR:US $3.76 USD -0.02

CUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $4.20 USD -0.07
Geron Corp $3.02 USD -0.13
International Stem Cell Corp $0.06 USD 0.00
Ocata Therapeutics Inc $7.22 USD -0.03
ReNeuron Group PLC 3.38 GBp 0.00
View Industry Companies
 

Industry Analysis

CUR

Industry Average

Valuation CUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19,810.7x
Price/Book 15.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17,980.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEURALSTEM INC, please visit www.neuralstem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.